Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SENATE PRODUCT LIABILITY BILL CAST AS SPUR TO ECONOMY

This article was originally published in The Gray Sheet

Executive Summary

SENATE PRODUCT LIABILITY BILL CAST AS SPUR TO ECONOMY by the five Senate sponsors who introduced the legislation March 31. The bipartisan measure was jointly introduced by principal author Sen. Jay Rockefeller (D-W.Va.) and four cosponsors: Sens. Christopher Dodd (D-Conn.), Joseph Lieberman (D-Conn.), Slade Gorton (R-Wash.) and John Danforth (R-Mo.). Rockefeller said the bill will "break the gridlock in our civil courts" and "bring new efficiencies to our economy." Lieberman asserted that the bill is both "pro-business and pro-consumer at the same time." Gorton maintained that product liability reform will both improve U.S. companies' international competitiveness and encourage development of products that previously were not developed due to liability concerns. Like past iterations of product liability reform legislation, this year's bill includes a government standards defense that exempts products subject to FDA review from liability for punitive damages, as long as their marketers have not withheld or misrepresented material information about the products. One difference between the current bill and S 640, introduced in the 102nd Congress by ex-Sen. Robert Kasten (R-Wis.), is that claimants no longer would be penalized for refusing to participate in an alternative dispute resolution in a case subsequently lost. On the other hand, defendant companies under the current bill must pay reasonable legal fees and costs for the claimant if they refuse to pursue expedited settlement and subsequently lose. Rockefeller explained that after one of last year's votes on S 640, "a number" of Democratic senators expressed concern about the provision penalizing injured parties who lose their cases. The new bill "entirely satisfies that particular sentiment," he said. Danforth and Rockefeller added that S 640 for "about 45 minutes" had a super majority of 60 votes required to pass the bill and end debate, but the bill failed after a few senators changed their votes. They feel the changed provision could give the new bill the boost needed for Senate endorsement. Information about the legislation has been presented to the White House, Rockefeller said. Although President Clinton has not given any commitment to support the legislation, Rockefeller said that, in the past, the President has given indications that he might endorse such a bill. President Clinton, when he was governor of Arkansas, "twice has voted with other governors to establish uniform national federal product liability laws," the West Virginia Democrat said. In addition, the President in February told business leaders "that he recognizes that there has to be some kind of change in the tort system, [although] he didn't specify" what changes he thought were necessary. Furthermore, Clinton "has talked from time to time about the alternative dispute resolution system, which is a state system, after all," Rockefeller said. "But having said that, there is no commitment from the White House at all."

You may also be interested in...



ICER Partnering With Aetion To Scale Up Use Of RWE In Value Assessments

Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.

‘Highly Questionable’ GMP Compliance In Pakistan Prompts New Licensing System

Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.

Infographic: 20 Years Of Mega-Deals

The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019. 

UsernamePublicRestriction

Register

MT000450

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel